Learning points
When observing a soft-tissue mass in or around a pacemaker pocket several months after pacemaker implantation, a malignant process should be part of the differential diagnosis.
The key to a fast and accurate diagnosis of a soft-tissue mass in or around a pacemaker pocket is ultrasound imaging and eventually ultrasound-guided tissue sampling.
PET-CT imaging is of added value to detect the eventuality of a primary tumour and for staging of the oncologic disease.
Introduction
Implantation of a cardiac implantable device is a routine procedure that should go along with careful post-operative monitoring of the device pocket in search for possible complications. Among the most frequent post-operative complications are: pocket haematoma, 1 pocket infection, 1 , 2 and cardiac device-related infective endocarditis (CDRIE). 2 Presentation of a primary tumour or a metastasis in a pacemaker pocket is rare, yet several case reports are available in the literature. 3–17 Reporting these rare cases is particularly relevant to understand the metastatic behaviour of tumours and their predilection for prosthetic material.
Timeline
| Day 0 | Successful two-chamber pacemaker implantation |
| Day 1, day 2 | Normal post-operative control, correct pacemaker function, clinically unremarkable pacemaker pocket |
| Day 84 | Normal routine outpatient check-up with normal pacemaker function and clinically unremarkable pocket |
| Day 272 | Routine outpatient check-up, patient reports no problems except a prominent mass in the pacemaker pocket, painless but annoying |
| Day 272 | Ultrasound imaging of soft-tissue mass, CT imaging, reveals soft-tissue mass around the pacemaker, haematoma or infection is excluded |
| Day 282 | Ultrasound-guided biopsy of soft-tissue mass is performed and sent for anatomopathological analysis |
| Day 289 | PET-CT imaging of total body reveals active oncologic process in the left lung hilum, the liver, mediastinal lymph nodes, bone lesions and a soft tissue mass around the pacemaker |
| Day 290 | Histopathological results of biopsy sample show evidence of a metastatic lesion of a squamous cell carcinoma |
| Day 302 | Multidisciplinary oncological assessment concludes that the patient suffers from an aggressive squamous cell carcinoma probably originating from the lung; patient refuses any form of anti-cancer treatment and consciously opts for palliative care |
| Day 318 | Patient deceased |
Case description
A 70-year-old male patient with a history of extensive nicotine abuse, laryngeal squamous cell carcinoma seven years ago, bladder urothelial carcinoma ten years ago, and a dual-chamber pacemaker (type Medtronic Azure XT W2DR01 MRI Surescan, an RV lead type Medtronic 5076 Capsure Fix Novus MRI 59 cm and an RA lead type Medtronic 5076 Capsure Fix Novus MRI 52 cm) implanted 9 months ago for sick sinus syndrome, was seen routinely in the outpatient cardiology clinic. He had complaints of persisting fatigue, dyspnoea, and coughing. He had been tested positive for COVID-19 infection three weeks earlier, but strangely his symptoms did not abate with time and were rather progressive. He also noted an evident, new swelling of his pacemaker pocket ( Figure 1A and B ). At the outpatient clinic, the patient had normal blood pressure, normal heart rate, no signs of cardiac decompensation or cachexia. Chest ultrasound suggested the presence of a soft tissue mass with increased vascularity, rather than a collection or a late haematoma ( Figure 1C and D ). The mass was also identified using conventional CT imaging ( Figure 2A–C ). Ultrasound-guided biopsy of the mass was obtained for histopathology and revealed a well differentiated invasive squamous cell carcinoma ( Figure 3A–C ). Additional PD-L1 staining was moderately positive ( Figure 3D ). PET-CT scan demonstrated FDG-avid lesions in the left lung hilum ( Figure 2B–D , arrowhead ) with multiple FDG-avid lesions present in the liver, as well as mediastinal lymph nodes and bone lesions. Furthermore, several soft tissue masses, among which a large mass surrounding the pacemaker pocket, were identified ( Figure 2 ).
The patient was subsequently referred for an oncologic assessment, but he refused to undergo further treatment and chose for palliative care. He died 1.5 months after his cardiology outpatient consultation where the mass was first noticed.
Discussion
To the best of our knowledge, we did not find any earlier reports of a squamous cell carcinoma of the lung metastasizing to a pacemaker pocket. Based on the tissue sampling and the PET-CT images, the multidisciplinary oncology team decided that the most likely primary origin of the metastasis was the tumour in the left lung. There are case reports and small case series describing metastatic lesions of melanoma, 3 malignant lesions in the proximity of breast carcinoma, 4–6 sarcoma, 7 , 8 rhabdomyosarcoma, 9 cutaneous leiomyosarcoma , 10 squamous cell and basocellular carcinoma of the skin, 11 , 12 non-Hodgkin lymphoma, 13 plasmablastic lymphoma , 14 plasmacytoma, 15 and multiple myeloma. 16
The detection of an active oncologic process, a primary tumour or a metastasis in a pacemaker pocket is a rare phenomenon. Depending on the time frame, after implantation of the device, primary causes of pocket swelling are pocket haematoma, inflammatory fluid collection, and pocket infection. A rare presentation of a merely local pocket infection with important fluid collection but without systemic inflammation has been described. 17 In the first place, ultrasound imaging of the swelling is the best tool to differentiate a soft-tissue mass from a blood collection. Whenever a soft-tissue mass is identified, an ultrasound-guided biopsy is a fast and reliable method to sample the tissue and a fast route towards a definite diagnosis. The result of the histopathology will then guide the oncologic staging process and the best additional examinations to be performed. In Figure 4 , we propose a comprehensive diagnostic work up, but additional or different tests might be necessary based on the identification and characterization of the primary tumour.
Based on other case reports, 5 , 16 the time frame between implantation of the device and occurrence of a tumour metastasis in this case, is rather short: in these other reports 5 , 16 it took years for this phenomenon to take place. Another interesting question that remains unanswered, is precisely why this pacemaker pocket was a predilection site for early metastasis. Literature is rather scarce, however two cases of a squamous lung carcinoma spreading to sites of ‘recent physical trauma’ have been described. 18
In the last decades, there were some reports on ‘oncotaxis’, the phenomenon describing the propensity of certain solid-tissue tumours to spread to zones of recent surgery (‘surgical oncotaxis’) 19 or chronic inflammation (‘inflammatory oncotaxis’). 20 Furthermore, it remains elusive whether the presence of titanium or other substances constituting a pacemaker battery, might have pro-oncogenic properties. As far as titanium is concerned, in vitro reports 21 and experiments in human subjects 22 have shown that titanium can induce chronic low-grade inflammation, e.g. by activating tissue macrophages overexpressing TNF-alpha. Potentially, this low-grade inflammation with an altered micro-environment in the pacemaker pocket is an attractive site for metastatic tumour cells.
Conclusions
When observing a soft-tissue mass in or around a pacemaker pocket months or years after pacemaker implantation, a malignant process should be part of the differential diagnosis. The key to a fast and accurate diagnosis is ultrasound imaging and eventually ultrasound-guided tissue sampling. PET-CT imaging is of added value to detect the eventuality of a primary tumour and for staging of the oncologic disease. Further research is warranted to understand which signals drive metastasis of an active cancer to a pacemaker pocket.
Lead author biography
Dr. Ward Heggermont is a board certified cardiologist, specialized in chronic heart failure, and device implantations, especially cardiac resynchronization therapy. He combines his clinical activities in the OLV Hospital Aalst (Belgium) with basic and translational research at the Cardiovascular Center Aalst (Belgium) and the Katholieke Universiteit Leuven.
Supplementary material
Supplementary material is available at European Heart Journal – Case Reports online.
Supplementary Material
Click here for additional data file.
Acknowledgements
We thank dr. Vanessa Meert (Pathology Department, OLV Hospital Aalst, Belgium) to provide the histopathological images for this case report.
Slide sets: A fully edited slide set detailing these cases and suitable for local presentation is available online as Supplementary data .
Consent: The authors confirm that written consent for submission and publication of this case report including images and associated text has been obtained from the patient’s next-of-kin in line with COPE guidance.
Conflict of interest: None declared.
Funding: None declared.
Contributor Information
Bert Popelier, Cardiovascular Center, OLV Hospital, Moorselbaan 164, 9300 Aalst, Belgium.
Ruben Vanheste, Department of Radiology, OLV Hospital, Moorselbaan 164, 9300 Aalst, Belgium.
Sofie Cuypers, Cardiovascular Center, OLV Hospital, Moorselbaan 164, 9300 Aalst, Belgium.
Ward Heggermont, Cardiovascular Center, OLV Hospital, Moorselbaan 164, 9300 Aalst, Belgium.
References
1. Klug D, Balde M, Pavin D, Hidden-Lucet F, Clementy J, Sadoul N, Rey JL, Lande G, Lazarus A, Victor J, Barnay C, Grandbastien B, Kacet S. Risk factors related to infections of implanted pacemakers and cardioverter-defibrillators: results of a large prospective study. Circulation 2007;116:1349–1355.
2. Glikson M, Nielsen JC, Kronborg MB, Michowitz Y, Auricchio A, Barbash IM, Barrabés JA, Boriani G, Braunschweig F, Brignole M, Burri H, Coats AJS, Deharo J-C, Delgado V, Diller G-P, Israel CW, Keren A, Knops RE, Kotecha D, Leclercq C, Merkely B, Starck C, Thylén I, Tolosana JM, ESC Scientific Document Group . 2021 ESC Guidelines on cardiac pacing and cardiac resynchronization therapy. Eur Heart J 2021;42:3427–3520.34455430
3. Golzio PG, Cristoforetti Y, Gaita F. Melanoma metastasis over a pacemaker pocket: integrated management strategies and facilitating factors. Europace 2013;15:1490.
4. Zonca P, Herokova J, Cambal M, Jacobi CA. Ductal carcinoma of the breast in the pacemaker generator's pocket. Bratisl Lek Listy 2009;110:719–722.
5. Rasmussen K, Grimsgaard C, Vik-Mo H, Stalsberg H. Male breast cancer from pacemaker pocket. Pacing Clin Electrophysiol 1985;8:761–763.
6. Biran S, Keren A, Farkas T, Stern S. Development of carcinoma of the breast at the site of an implanted pacemaker in two patients. J Surg Oncol 1979;11:7–11.
7. Khamooshian A, Klinkenberg TJ, Maass AH, Mariani MA. Management of device-related malignant sarcoma. HeartRhythm Case Rep 2017;3:373–376.
8. Fraedrich G, Kracht J, Scheld HH, Jundt G, Mulch J. Sarcoma of the lung in a pacemaker pocket–simple coincidence or oncotaxis? Thorac Cardiovasc Surg 1984;32:67–69.
9. Carpentier O, Dubost-Brama A, De Lassalle E M, Piette F, Delaporte E. Rhabdomyosarcoma at site of pacemaker implantation. Ann Dermatol Venereol 2000;127:837–840.
10. González-Vela MC, Val-Bernal JF, Rubio S, Olalla JJ, González-López MA. Cutaneous leiomyosarcoma developing on a pacemaker pocket. Dermatol Surg 2009;35:863–867.
11. Kang D, Do K, Nattiv J, Zareh M, Doshi R. Malignant transformation of a chronically infected implantable cardioverter-defibrillator pocket. HeartRhythm Case Rep 2018;4:307–309.
12. Reyes CV. Clear cell hidradenocarcinoma developing in pacemaker pocket. Pacing Clin Electrophysiol 2008;31:1513–1515.
13. Hojo N, Yakushijin Y, Narumi H, Minamoto Y, Sakai I, Takada K, Yasukawa M, Fujita S, Hato T. Non-Hodgkin’s lymphoma developing in a pacemaker pocket. Int J Hematol 2003;77:387–390.
14. Zarifi C, Deutsch S, Dullet N, Mukherjee KK, Mukherjee A, Abubaker F. An enlarging pacemaker pocket: A case report of a plasmablastic lymphoma arising as a primary tumor around a cardiac pacemaker and systematic literature review of various malignancies arising at the pacemaker pocket. J Cardiol Cases 2018;17:41–43.
15. Hamaker WR, Lindell ME, Gomez AC. Plasmacytoma arising in a pacemaker pocket. Ann Thorac Surg 1976;21:354–356.
16. Sasaki M, Katoh Y, Niwakawa M, Andoh A, Hodohara K, Fujiyama Y, Bamba T, Hosoda S, Kanoh T. Multiple myeloma with a mass formation in a pacemaker pocket. Rinsho Ketsueki 1992;33:1747–1752.
17. Aktuerk D, Lutz M, Luckraz H. Images in emergency medicine. An unusual swelling at the pacemaker pocket site. Pacemaker pocket infection caused by Stenotrophomonas maltophilia. Ann Emerg Med 2014;63:391. 403.
18. Walter ND, Rice PL, Redente EF, Kauvar EF, Lemond L, Aly T, Wanebo K, Chan ED. Wound healing after trauma may predispose to lung cancer metastasis: review of potential mechanisms. Am J Respir Cell Mol Biol 2011;44:591–596.
19. Hirai T, Matsumoto H, Yamashita K, Urakami A, Iki K, Yamamura M, Tsunoda T. Surgical oncotaxis–excessive surgical stress and postoperative complications contribute to enhancing tumor metastasis, resulting in a poor prognosis for cancer patients. Ann Thorac Cardiovasc Surg 2005;11:4–6.
20. Shine T, Wallack MK. Inflammatory oncotaxis after testing the skin of the cancer patient. Cancer 1981;47:1325–1328.
21. Olmedo DG, Tasat DR, Evelson P, Guglielmotti MB, Cabrini RL. Biological response of tissues with macrophagic activity to titanium dioxide. J Biomed Mater Res A 2008;84:1087–1093.
22. Lechner J, Noumbissi S, von Baehr V. Titanium implants and silent inflammation in jawbone-a critical interplay of dissolved titanium particles and cytokines TNF-α and RANTES/CCL5 on overall health? EPMA J 2018;9:331–343.
Associated Data
Supplementary Materials
Click here for additional data file.